DT09 Rec'd PCT/PTO 26 AUG 2005

r 				T			s	heet <u>1</u> of	<u>f </u>
Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office			ATTY. DOCKET NO. VB60107	INTERNATIONAL APPLICATION NO. PCT/EP2004/001850 10/547206					
INFORI	MATION DISCLOSUR	APPLICANT							
BY APPLICANT (Use several sheets if necessary)				Alain JACQUET					
				FILING DATE			GROUP		
				Herewith	า				
		U.S	S. PATENT	DOCUMENTS					
Examiner Initial	Document Number	Date		Name	C	Class	Subclass	Filing Date If Appropriate	
		FORE	IGN PATE	NT DOCUMENTS					
	Document Number	Date	e	Country	Clas	SS	Subclass	<u>Trans</u> Yes	<u>slation</u> No
	WO 01/96385	250 26-Sep-2002		PCT					
	WO 02/074250			PCT					
	WO 99/25823			PCT		·			
	WO 03/016340	27-Feb-2003		PCT					
	WO 92/04445	19-Mar-1992		PCT					
	WO 0196385	20-Dec-	2001	PCT					
	WO 02074250	26-Sep-2002		PCT					
	WO 9925823	27-May-	1999	PCT					
	WO 03016340	27-Feb-2	2003	PCT					
	WO 9204445	19-Mar-	1992	PCT					<u></u>
				ıthor, Title, Date, Pertir					
	processing which Allergy and Clinic	is depende cal Immun	ent of the c ology, <u>107</u>		activity	of th	ne allergen."	Journa	al of
	Shakib F, et al., "The proteolytic activity of Der p 1 selectively enhances IgE synthesis: A link between allergenicity and cysteine protease activity." Clinical and Experimental Allergy, 30(6): 751-752 (2000). Jacquet A, et al., "Absence of immunoglobulin E synthesis and airway eosinophilia by vaccination with plasmid DNA encoding ProDer p 1." Clinical and Experimental Allergy, 33(2): 218-225 (2003).								
				<u></u>			·····		
EXAMINER /Nora Rooney/				DATE CONSIDERED 11/20/2008					
	Initial if citation considered eand not considered. Inc						raw line throug	h citation	if not

n:\erg\apps\vb cases\60107\vb60107 national stage.doc